Rafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rafferty Asset Management LLC decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 11.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 595,472 shares of the company's stock after selling 80,319 shares during the period. Rafferty Asset Management LLC owned about 0.15% of Recursion Pharmaceuticals worth $4,025,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RXRX. Private Trust Co. NA purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at $27,000. Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after purchasing an additional 6,758 shares in the last quarter. Finally, Colonial River Investments LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $68,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of research reports. Needham & Company LLC cut their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Morgan Stanley lowered their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $4.56 on Monday. The company's 50-day moving average is $5.34 and its two-hundred day moving average is $6.59. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -2.98 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm posted ($0.39) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.